<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Peptide hormone signal transduction and regulation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Peptide hormone signal transduction and regulation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Peptide hormone signal transduction and regulation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rodger A Liddle, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Benjamin A Raby, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Signal transduction is a process by which a peptide hormone transfers specific information from the outside of the target cell to elicit a cellular response. For this to occur, the hormone (eg,
         <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">
          secretin
         </a>
         ) exerts a signal through a specific receptor that transmits information from the extracellular compartment (eg, blood) into the cell. For example, in the gastrointestinal tract, secretin is released from cells in the duodenum and is taken by the blood to the pancreas, where it binds specific receptors on duct cells. Secretin binding to its receptor initiates a signaling cascade that generates the second messenger, cyclic adenosine monophosphate (cAMP), resulting in secretion of fluid rich in bicarbonate. The transfer of information from the outside to the inside of the cells is tightly controlled, especially in settings that are vital for cellular homeostasis.
        </p>
        <p>
         The normal function of a cell depends upon an intact signal regulation/termination system. If this system malfunctions, the host may experience pathophysiologic consequences, such as abnormal secretion, motility, growth, or even the development of cancer [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         There are three major categories of cell-surface peptide receptors that are based on their structure and signaling mechanisms. These include G protein-coupled receptors (GPCRs), enzyme-coupled receptors, and ion channel-coupled receptors.
        </p>
        <p>
         The major physiologic principles of cell signaling systems will be reviewed here. Discussions of individual peptide hormones are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/2534.html" rel="external">
          "Overview of gastrointestinal peptides in health and disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2558.html" rel="external">
          "Physiology of cholecystokinin"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2551.html" rel="external">
          "Physiology of gastrin"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          RECEPTOR STIMULATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the vast array of information communicated to a cell, the basic components of the signaling system are relatively simple (
         <a class="graphic graphic_figure graphicRef74916" href="/z/d/graphic/74916.html" rel="external">
          figure 1
         </a>
         ). A peptide hormone binds to a cell-surface receptor and stimulates activation of an effector system. Cell-surface receptors are capable of interacting with only certain chemical messages. The specificity of the hormone-receptor interaction is responsible for the unique cellular response.
        </p>
        <p>
         The peptide hormone must initiate a change in the receptor such that the hormone-receptor complex activates an intracellular effector molecule, such as a specific guanyl-nucleotide-binding protein (G protein) (
         <a class="graphic graphic_figure graphicRef79723" href="/z/d/graphic/79723.html" rel="external">
          figure 2
         </a>
         ). Most peptide hormone receptors act through G proteins; as a result, these receptors are called G protein-coupled receptors (GPCRs).
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          G proteins
         </span>
         <span class="headingEndMark">
          —
         </span>
         G proteins are molecular intermediaries that initiate the intracellular communication process (
         <a class="graphic graphic_figure graphicRef79723" href="/z/d/graphic/79723.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid3">
          3,4
         </a>
         ]. After the hormone binds to its receptor, a G protein is stimulated. Stimulation begins the intracellular process of signal transduction.
        </p>
        <p>
         G proteins are composed of three subunits (alpha, beta, and gamma) and are classified according to their alpha subunit. G proteins that stimulate adenylyl cyclase are classified as the Gs type; those that inhibit adenylyl cyclase are called Gi. To date, 20 different G protein alpha subunits have been identified [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Shortly after receptor stimulation, a series of events are initiated, which ultimately act to turn off signaling. The principal events in this process involve receptor desensitization and internalization, which re-establish cell responsiveness. (See
         <a class="local">
          'Desensitization'
         </a>
         below and
         <a class="local">
          'Internalization'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          G protein-coupled receptors
         </span>
         <span class="headingEndMark">
          —
         </span>
         GPCRs are heptahelical proteins with seven membrane-spanning domains [
         <a href="#rid5">
          5
         </a>
         ]. They contain an extracellular amino terminus and an intracellular carboxy terminus (
         <a class="graphic graphic_figure graphicRef63760" href="/z/d/graphic/63760.html" rel="external">
          figure 3
         </a>
         ). When stimulated by the appropriate chemical messenger, the GPCR undergoes a conformational change that causes coupling to a specific G protein. With improved understanding of receptor structure using radiograph crystallography and computer modeling, GPCRs are becoming more attractive as drug targets [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         GPCRs are classified by their structure into three groups (
         <a class="graphic graphic_table graphicRef52173" href="/z/d/graphic/52173.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group I, the largest group, contains the receptors for catecholamines, many peptide hormones, neuropeptides, and glycoproteins
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group II contains the
         <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">
          secretin
         </a>
         /glucagon/vasoactive intestinal peptide receptor family
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group III contains the metabotropic receptors (eg, calcium-sensing and glutamate receptors)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Effector systems
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following receptor occupation, G protein subunits cause activation of enzymes or other proteins, ultimately resulting in a variety of cellular responses (
         <a class="graphic graphic_figure graphicRef58612" href="/z/d/graphic/58612.html" rel="external">
          figure 4
         </a>
         ). Enzymes, such as adenylyl cyclase or phospholipase C, generate specific second messengers; examples include cyclic adenosine monophosphate (cAMP), inositol 1,4,5 trisphosphate (IP3), and diacylglycerol. Some G proteins couple directly with specific ion channels, such as potassium or calcium channels, and initiate changes in ion permeability (
         <a class="graphic graphic_figure graphicRef58612" href="/z/d/graphic/58612.html" rel="external">
          figure 4
         </a>
         ). The effector systems are not understood for some receptors, such as receptors involved with cell growth and differentiation (
         <a class="graphic graphic_table graphicRef82351" href="/z/d/graphic/82351.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Adenylate cyclase
         </span>
         <span class="headingEndMark">
          —
         </span>
         One of the most studied effector systems of receptor activation is the production of cAMP. As discussed above, Gs-coupled G protein-coupled receptors stimulate adenylate cyclase to produce cAMP. A conformational change occurs as the hormone binds to its receptor allowing the receptor to associate with Gs. Under basal (unstimulated) conditions, Gs is bound to guanosine diphosphate (GDP). However, GDP is released during hormone binding and is replaced with guanosine triphosphate (GTP). The Gs-GTP complex then activates adenylyl cyclase, resulting in the formation of cAMP from adenosine triphosphate (ATP) within the cytoplasm of the cell. cAMP is then capable of producing other effects within the cell, ultimately leading to responses such as secretion, motility, or growth.
        </p>
        <p>
         The G alpha-GTP complex is gradually inactivated by GTPase, which converts GTP to GDP. This enzymatic conversion occurs spontaneously by the G protein, which is itself a GTPase. The conversion of GTP to GDP no longer permits G protein stimulation of adenylate cyclase and is one way by which the hormone signal is terminated and the basal condition is restored.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Phospholipase C
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other G proteins, such as Go, activate the phosphoinositide system when bound to hormone. Phospholipase C (PLC) acts on inositol phospholipids found in the cell membrane. As an example, PLC can cause the hydrolysis of phosphatidylinositol 4,5 bisphosphate (PIP2) to 1,2 diacylglycerol and IP3. Diacylglycerol and IP3 can then act as regulators of cell metabolism. This pathway can alter cell function by increasing intracellular calcium levels.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          SIGNAL REGULATION AND TERMINATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Even while signal transduction is occurring, processes begin that will terminate receptor responsiveness.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Desensitization
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the cell to respond to future stimuli, signaling must be terminated completely and in a timely fashion, a process known as desensitization. Desensitization begins within seconds to minutes of hormone binding and eventually results in signal termination [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Desensitization is the primary regulatory step that assures appropriate cell function. It involves the termination of receptor activation by receptor phosphorylation, which is initiated by specific G protein-coupled receptor kinases (GRKs) or second messenger-dependent kinases (eg, protein kinase A and protein kinase C).
        </p>
        <p>
         Phosphorylation of receptors requires the recruitment of proteins to the hormone-receptor complex, which participate in regulating signaling. One of these is beta-arrestin, which is located in the cytoplasm of unstimulated cells [
         <a href="#rid8">
          8
         </a>
         ]. Upon hormone receptor stimulation, beta-arrestin is translocated from the cytoplasm to the cell membrane and assists in signal termination and subsequent hormone-receptor internalization [
         <a href="#rid8">
          8-10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Internalization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the receptor is adequately phosphorylated, the hormone-receptor complex is moved from the cell membrane to the inside of the cell, a process known as "internalization." Internalization, which may also involve beta-arrestins [
         <a href="#rid10">
          10
         </a>
         ], permits receptor processing to occur, which will most likely result in receptor dephosphorylation, removal/degradation of the peptide hormone, and receptor degradation or recycling. Regardless of the eventual fate of the hormone-receptor complex, the goal is to re-establish cell responsiveness, so the next hormone stimulus is capable of sending the necessary information into the cell.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Beta-arrestin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Arrestins are cytosolic proteins that are recruited to hormone-bound receptors and bind to cytoplasmic regions of the receptor [
         <a href="#rid11">
          11
         </a>
         ]. Once bound with beta-arrestin, the hormone-receptor complex is "targeted" to a specific endocytic pathway that turns off the signaling process. Endocytosis is the process by which the hormone-occupied receptor is brought from the plasma membrane into the cell. The eventual fate of the receptor depends in part upon the receptor type. Some receptors are rapidly internalized and recycled back to the cell membrane, while others are destroyed and only newly produced receptors are expressed on the cell surface. While beta-arrestins were first identified by their ability to desensitize G protein-coupled receptors (GPCRs), it has been recognized that they can stimulate signaling pathways independent of G protein activation [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Enzyme-coupled receptors
         </span>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Receptor tyrosine kinases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some peptides signal through receptors that are not linked to G proteins but instead are coupled to enzymes that phosphorylate specific intracellular proteins and elicit a cellular response, such as growth. These receptors are primarily targets for growth factors, such as epidermal growth factor (EGF). The most representative of these receptors possesses intrinsic protein tyrosine kinase activity. These receptors are comprised of an extracellular domain that is usually glycosylated, a single transmembrane domain, and a cytoplasmic domain that contains a protein tyrosine kinase region and a region that is a substrate for peptide ligand-activated phosphorylation. When activated, these receptors transfer adenosine triphosphate (ATP) to specific intracellular proteins.
        </p>
        <p>
         With peptide binding, these receptors either phosphorylate themselves or are phosphorylated by other protein kinases [
         <a href="#rid13">
          13
         </a>
         ]. After activation, these receptors initiate other intracellular signal transduction pathways, including Ras, which activates MAP kinase. MAP kinase, in turn, modulates other cellular proteins, particularly transcription factors. Specific phosphorylated tyrosine residues are also binding sites for Src homology regions 2 and 3 (SH2 and SH3 domains) that can activate various signaling pathways [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Examples of the receptor tyrosine kinase family include receptors for EGF, insulin, insulin-like growth factor, fibroblast growth factor, vascular endothelial growth factor, platelet-derived growth factor, nerve growth factor, and macrophage colony-stimulating factor [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Receptor serine/threonine kinases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Receptor serine/threonine kinases such as transforming growth factor beta (TGF-beta) receptors contain a single transmembrane domain. Stimulation of these receptors activates endogenous serine/threonine kinase activity, which modulates cellular protein function [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H420927624">
         <span class="h2">
          Ion channel-coupled receptors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ion channels are key regulators of neurons and muscle cells, and control of ion channels is critical for neurotransmission and muscle contraction. Ion channel-coupled receptors reside in the cell membrane and are involved in processes that require rapid signaling, such as neurotransmission. Typically, the receptor itself is an ion channel that opens and closes, allowing the flow of ions such as sodium (Na
         <sup>
          +
         </sup>
         ), potassium (K
         <sup>
          +
         </sup>
         ), calcium (Ca
         <sup>
          2+
         </sup>
         ), or chloride (Cl
         <sup>
          -
         </sup>
         ) into or out of the cell [
         <a href="#rid17">
          17
         </a>
         ]. The directional flow of ions depends on the concentration of the respective ions inside or outside the cell. The flow of ions regulates the electrical excitability of the cell and is intimately coupled to cellular responses, such as neurotransmission, fluid and electrolyte secretion, or hormone release [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          PHYSIOLOGIC NUTRIENT SENSING
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of G protein-coupled receptors (GPCRs) originally identified in other tissues have been found in the gastrointestinal tract and may sense nutrients in the intestinal lumen. Many of these receptors respond to amino acids or protein proteolytic degradation products, fatty acids, or carbohydrates and include receptors such as the calcium-sensing receptor, the GPCR family C, taste receptors, and free fatty acid-sensing receptors [
         <a href="#rid19">
          19-21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          PATHOPHYSIOLOGIC RELEVANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dysfunction of the control mechanisms of cellular signaling may lead to a number of pathophysiologic consequences [
         <a href="#rid22">
          22
         </a>
         ]. Over 600 "loss-of-function" mutations of G protein-coupled receptors (GPCRs) have been described that result in impaired receptor signaling and possibly disease (
         <a class="graphic graphic_table graphicRef90175" href="/z/d/graphic/90175.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid23">
          23-25
         </a>
         ]. In contrast, unregulated stimulation in the absence of hormone (constitutive activity) is a feature of "gain-of-function" mutations. Over 100 activating mutations have been described, accounting for over 30 human diseases (
         <a class="graphic graphic_table graphicRef90176" href="/z/d/graphic/90176.html" rel="external">
          table 4
         </a>
         ). As examples, a constitutively active receptor has been found in thyroid adenomas producing clinical hyperthyroidism [
         <a href="#rid26">
          26
         </a>
         ] and in precocious puberty secondary to a mutation in the luteinizing hormone receptor [
         <a href="#rid27">
          27
         </a>
         ]. On the other hand, the McCune-Albright syndrome is due to postzygotic activating mutations in the gene encoding the G alpha s protein, resulting in activation of the signal-transduction pathway generating cyclic adenosine monophosphate (cAMP) [
         <a href="#rid28">
          28-30
         </a>
         ]. The clinical manifestations include polyostotic fibrous dysplasia, cafe au lait spots, and hyperfunction of multiple glands that can lead to sexual precocity, Cushing's syndrome, acromegaly, hyperthyroidism, or hyperparathyroidism.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          SUMMARY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Signal transduction is a process in which a peptide hormone transfers specific information from the outside of the target cell to exert a cellular response. For this to occur, the hormone exerts a signal through a specific receptor that transmits information from the extracellular compartment into the cell. The transfer of information from the outside to the inside of the cells is tightly controlled, especially in settings that are vital for cellular homeostasis (
         <a class="graphic graphic_figure graphicRef74916" href="/z/d/graphic/74916.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         There are three major categories of cell surface peptide receptors that are based on their structure and signaling mechanisms. These include G protein-coupled receptors (GPCRs), enzyme-coupled receptors, and ion channel-coupled receptors. With improved understanding of receptor structure using radiograph crystallography and computer modeling, GPCRs are becoming more attractive as drug targets (
         <a class="graphic graphic_table graphicRef52173" href="/z/d/graphic/52173.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef90175" href="/z/d/graphic/90175.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef90176" href="/z/d/graphic/90176.html" rel="external">
          table 4
         </a>
         ).
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lefkowitz RJ. G proteins in medicine. N Engl J Med 1995; 332:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krontiris TG. Oncogenes. N Engl J Med 1995; 333:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaughan M. Signaling by heterotrimeric G proteins minireview series. J Biol Chem 1998; 273:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neer EJ. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 1995; 80:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002; 3:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason JS, Bortolato A, Congreve M, Marshall FH. New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol Sci 2012; 33:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okashah N, Wan Q, Ghosh S, et al. Variable G protein determinants of GPCR coupling selectivity. Proc Natl Acad Sci U S A 2019; 116:12054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krupnick JG, Benovic JL. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 1998; 38:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranganathan R, Stevens CF. Arrestin binding determines the rate of inactivation of the G protein-coupled receptor rhodopsin in vivo. Cell 1995; 81:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferguson SS, Downey WE 3rd, Colapietro AM, et al. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996; 271:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science 2005; 308:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibrahim IA, Kurose H. β-arrestin-mediated signaling improves the efficacy of therapeutics. J Pharmacol Sci 2012; 118:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 2004; 116:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon MA. Receptor tyrosine kinases: specific outcomes from general signals. Cell 2000; 103:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgoyne RD, Haynes LP. Sense and specificity in neuronal calcium signalling. Biochim Biophys Acta 2015; 1853:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubin AE, Patapoutian A. Nociceptors: the sensors of the pain pathway. J Clin Invest 2010; 120:3760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wellendorph P, Johansen LD, Bräuner-Osborne H. Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. Mol Pharmacol 2009; 76:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reimann F, Tolhurst G, Gribble FM. G-protein-coupled receptors in intestinal chemosensation. Cell Metab 2012; 15:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wauson EM, Lorente-Rodríguez A, Cobb MH. Minireview: Nutrient sensing by G protein-coupled receptors. Mol Endocrinol 2013; 27:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farfel Z, Bourne HR, Iiri T. The expanding spectrum of G protein diseases. N Engl J Med 1999; 340:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöneberg T, Schulz A, Biebermann H, et al. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther 2004; 104:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vassart G, Costagliola S. G protein-coupled receptors: mutations and endocrine diseases. Nat Rev Endocrinol 2011; 7:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöneberg T, Liebscher I. Mutations in G Protein-Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approaches. Pharmacol Rev 2021; 73:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parma J, Duprez L, Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shenker A, Laue L, Kosugi S, et al. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993; 365:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringel MD, Schwindinger WF, Levine MA. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 1996; 75:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325:1688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993; 123:509.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3804 Version 14.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7800014" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : G proteins in medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7596376" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Oncogenes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9422712" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Signaling by heterotrimeric G proteins minireview series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7834744" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Heterotrimeric G proteins: organizers of transmembrane signals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12209124" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Seven-transmembrane receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22465153" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : New insights from structural biology into the druggability of G protein-coupled receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31142646" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Variable G protein determinants of GPCR coupling selectivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9597157" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The role of receptor kinases and arrestins in G protein-coupled receptor regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7781061" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Arrestin binding determines the rate of inactivation of the G protein-coupled receptor rhodopsin in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8553074" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15845844" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Transduction of receptor signals by beta-arrestins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22447307" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : β-arrestin-mediated signaling improves the efficacy of therapeutics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11057895" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cell signaling by receptor tyrosine kinases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14744431" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11051543" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Receptor tyrosine kinases: specific outcomes from general signals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12809600" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mechanisms of TGF-beta signaling from cell membrane to the nucleus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25447549" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Sense and specificity in neuronal calcium signalling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21041958" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nociceptors: the sensors of the pain pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487246" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22482725" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : G-protein-coupled receptors in intestinal chemosensation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23820899" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Minireview: Nutrient sensing by G protein-coupled receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10099144" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The expanding spectrum of G protein diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15556674" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Mutant G-protein-coupled receptors as a cause of human diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21301490" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : G protein-coupled receptors: mutations and endocrine diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33219147" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Mutations in G Protein-Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8413627" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7692306" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8699958" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1944469" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8410501" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
